Thalys(SH:603716) Ge Long Hui A P P·2025-09-17 11:46Core Viewpoint - The company, Saily Medical (603716.SH), has approved a capital increase in its subsidiary, Wuhan Huajiyuan, which will enhance its ownership stake and support the development of a therapeutic hypertension vaccine project [1] Group 1: Investment Details - The company plans to invest 42.7429 million yuan in Wuhan Huajiyuan, increasing its ownership from 30% to 41% [1] - The actual controller, Mr. Wen Wei, will acquire an additional 10% stake in Wuhan Huajiyuan for 27.2 million yuan, with other shareholders waiving their preemptive rights [1] - The total investment from the company and Mr. Wen Wei amounts to 69.9429 million yuan [1] Group 2: Strategic Implications - The capital increase will provide additional funding to Wuhan Huajiyuan, facilitating the clinical trials of the therapeutic hypertension vaccine (HJY-ATRQβ-001) [1] - This investment aligns with the company's strategic transformation plan, optimizing its business structure and enhancing core competitiveness [1] - The investment is expected to promote sustainable and steady development for the company [1]